Indications for: VAQTA
Hepatitis A immunization.
≥19 yrs: 1mL IM at elected date and booster dose (1mL IM) 6–18 months later.
<12 months: not recommended. 1–18 yrs: 0.5mL IM at elected date and booster dose (0.5mL IM) 6–18 months later.
Have epinephrine (1:1000) available. Latex allergy. Inject into deltoid muscle, preferably at least 2 weeks before expected exposure. If given with immune globulin, use separate syringe and different site. Fever. Malignancies. Immunocompromised (may have suboptimal response). Bleeding disorders. Pregnancy (Cat.C). Nursing mothers.
Immunosuppressives may reduce efficacy. Concomitant vaccines, immune globulins: see literature.
Injection site reactions (esp. pain, tenderness), headache, fever, GI upset, myalgia, abdominal pain, rash, pharyngitis and other upper respiratory tract effects.
Prefilled syringes (0.5mL, 1mL)—1, 5; Single-dose vials (0.5mL)—1, 10; Single-dose vials (1mL)—1, 5, 10